BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahmed OA, Safwat E, Khalifa MO, Elshafie AI, Fouad MHA, Salama MM, Naguib GG, Eltabbakh MM, Sherief AF, Abd-Elsalam S. Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village. Int J Hepatol 2018;2018:9616234. [PMID: 29755792 DOI: 10.1155/2018/9616234] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Mahran SA, Mohamed AAA, Nigm DA, Rahma MZAA, Abd-elsalam S, Hamoud H, Hamdy M, Risha MI, Hamdy A, Abdelkareem MM, Ghanem S, Hanafy M, Moshrif A, Fehr A, Elnouby FH, Osman A, Hassanien MM. Subclinical hepatitis C virus infection in Egyptian patients with rheumatic diseases: a multi-center study. Egypt Rheumatol Rehabil 2020;47. [DOI: 10.1186/s43166-020-00014-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Elbahrawy A, Ibrahim MK, Eliwa A, Alboraie M, Madian A, Aly HH. Current situation of viral hepatitis in Egypt. Microbiol Immunol 2021;65:352-72. [PMID: 33990999 DOI: 10.1111/1348-0421.12916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Elbedewy TA, Elsebaey MA, Elshweikh SA, Elashry H, Abd-Elsalam S. Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia. Ther Clin Risk Manag 2019;15:269-74. [PMID: 30804674 DOI: 10.2147/TCRM.S186106] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ali ME, Halby HM, Ali MY, Hassan EA, El-Mokhtar MA, Sayed IM, Thabet MM, Fouad M, El-Ashmawy AM, Mahran ZG. Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents. Viruses 2021;13:2008. [PMID: 34696438 DOI: 10.3390/v13102008] [Reference Citation Analysis]
5 Helal EM, Sharaf-Eldin M, Abou El Azm AR, Badr Eldin NM, Dawoud MM, Abd-Elsalam S, Ziada DH. Hemodynamic Changes of Hepatic & Renal Vessels in Systemic Bacterial Infection with Fever in HCV Related Cirrhosis. Infect Disord Drug Targets 2020;20:511-6. [PMID: 31057113 DOI: 10.2174/1871526519666190506102703] [Reference Citation Analysis]
6 Umutesi J, Liu CY, Penkunas MJ, Makuza JD, Ntihabose CK, Umuraza S, Niyikora J, Serumondo J, Gupta N, Nsanzimana S. Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population. BMJ Open 2019;9:e029743. [PMID: 31272986 DOI: 10.1136/bmjopen-2019-029743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
7 Said EM, Abdulaziz BA, El Kassas M, El Attar IH, Emadeldeen M, Abd-Elsalam SM. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Arch Virol 2020;165:1633-9. [PMID: 32356185 DOI: 10.1007/s00705-020-04639-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Naguib GG, Michael TG, Elshazly Y, Wahdan MM, Mostafa A, Ahmed OA, Dabbous H, Aly HIS, Shaker MK, Elbaz HS, El-Serafy M, Doss W, Abd-Elsalam S, El-Sayed MH. The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. Virusdisease 2021;32:582-8. [PMID: 34631983 DOI: 10.1007/s13337-021-00712-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yosef T, Ibrahim WA, El-ghandour A, Attia S, El-nakeep S. Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00075-8] [Reference Citation Analysis]
10 El-Tahan RR, Ghoneim AM, Zaghloul H. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients. Virus Genes 2020;56:564-81. [PMID: 32572756 DOI: 10.1007/s11262-020-01776-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ibrahim Mohammed Ebid AH, Ashraf Ahmed O, Hassan Agwa S, Mohamed Abdel-Motaleb S, Mohamed Elsawy A, Hagag RS. Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients. J Clin Pharm Ther 2020;45:539-46. [PMID: 31889322 DOI: 10.1111/jcpt.13104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Alhaddad O, Wahb A, Sabry A, Khalil F, Elsabaawy D, Elshazly H, Shebl N, Rady M, Elsabaawy M. Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C. Expert Rev Anti Infect Ther 2020;18:817-22. [PMID: 32397842 DOI: 10.1080/14787210.2020.1758557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
14 Mekky MA, Sayed HI, Abdelmalek MO, Saleh MA, Osman OA, Osman HA, Morsy KH, Hetta HF. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study. Infect Drug Resist. 2019;12:273-279. [PMID: 30774394 DOI: 10.2147/idr.s181638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
15 Saleh AM, Hassan EA, Gomaa AA, El Baz TM, El-Abgeegy M, Seleem MI, Abo-Amer YE, Elsergany HF, Mahmoud EIE, Abd-Elsalam S. Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt. Infect Drug Resist 2019;12:2277-82. [PMID: 31413604 DOI: 10.2147/IDR.S208954] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Mohamed AA, El-Toukhy NER, Said EM, Gabal HMR, AbdelAziz H, Doss W, El-Hanafi H, El Deeb HH, Mahmoud S, Elkadeem M, Shalby HS, Abd-Elsalam S. Hepatitis C Virus: Efficacy of New DAAs Regimens. Infect Disord Drug Targets 2020;20:143-9. [PMID: 30663575 DOI: 10.2174/1871526519666190121114003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
17 Mohamed IEL, El-saeed KM, Al-sadik MH, Anwar CA. Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00089-5] [Reference Citation Analysis]
18 Abo-Amer YE, Badawi R, El-Abgeegy M, Elsergany HF, Mohamed AA, Mostafa SM, Alegaily HS, Soliman S, Elnawasany S, Abd-Elsalam S. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Adv Virol 2020;2020:9075905. [PMID: 32774374 DOI: 10.1155/2020/9075905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 El-Bendary M, Abd-Elsalam S, Elbaz T, El-Akel W, Cordie A, Elhadidy T, Elalfy H, Farid K, Elegezy M, El-Badrawy A, Neamatallah M, Abd Elghafar M, Salama M, AbdAllah M, Essam M, El-Shazly M, Esmat G. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther 2021;:1-5. [PMID: 34225541 DOI: 10.1080/14787210.2021.1950532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Abo-Amer YE, Abd-Elsalam S, Eldosoky H, ELShenawy AK, Awny S, Elagawy W, Abgeegy ME, Elsergany HF, Elashry H, Negm MS. Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt. Infect Drug Resist 2018;11:2435-41. [PMID: 30538509 DOI: 10.2147/IDR.S183462] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Soliman H, Ziada D, Salama M, Hamisa M, Badawi R, Hawash N, Selim A, Abd-Elsalam S. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study. Endocr Metab Immune Disord Drug Targets 2020;20:104-11. [PMID: 31448717 DOI: 10.2174/1871530319666190826150344] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
22 Abd-Elsalam S, Abo-Amer YE, El-Abgeegy M, Elshweikh SA, Elsergany HF, Ahmed R, Elkadeem M, Hawash N, Soliman S, Badawi R, Elguindy AMA, Soliman MY, Mohmed AA, Mansour L. Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience. Medicine (Baltimore) 2020;99:e21972. [PMID: 33080669 DOI: 10.1097/MD.0000000000021972] [Reference Citation Analysis]
23 El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol 2019;20:163-74. [PMID: 31585703 DOI: 10.1016/j.ajg.2019.09.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Keikha M, Eslami M, Yousefi B, Ali-Hassanzadeh M, Kamali A, Yousefi M, Karbalaei M. HCV genotypes and their determinative role in hepatitis C treatment. Virusdisease 2020;31:235-40. [PMID: 32904762 DOI: 10.1007/s13337-020-00592-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
25 Abo-Elenein AM, Mabrouk MM, Abou-Saif S, Saeed OM, Khodeir S, Elkadeem M, Elashry H, Haydara T, Zaghloul MS, Seleem WM, Elshweikh SA, Abd-Elsalam S. Role of Both Protein C and Antithrombin III as Predictors of Stage of Liver Disease in Chronic Viral Hepatitis B or C Infected Patients. Endocr Metab Immune Disord Drug Targets 2020;20:112-7. [PMID: 31142255 DOI: 10.2174/1871530319666190529092555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Elsayed A, M Abdelraheem E, Hassan H, Abbas A, Hassnine A. Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect? BMJ Open Gastroenterol 2020;7:e000533. [PMID: 33310750 DOI: 10.1136/bmjgast-2020-000533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Hany NM, Hammouda AMA, Nabih ES, Mohamed SM. The potential regulatory role of miR16 to the interplay between interferon and transforming growth factor beta pathways through IRF3 and SMAD7 in hepatitis C virus infected patients. J Cell Biochem 2019;120:12694-701. [PMID: 30861602 DOI: 10.1002/jcb.28537] [Reference Citation Analysis]
28 Ebid AIM, Ahmed OA, Agwa SH, Abdel-Motaleb SM, Hagag RS. Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients. Int J Clin Pharm 2020;42:1207-16. [PMID: 32712884 DOI: 10.1007/s11096-020-01085-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Tran AN, Lim JK. Hepatitis C: How Good Are Real-Life Data and Do Generics Work. Gastroenterol Clin North Am 2020;49:279-99. [PMID: 32389363 DOI: 10.1016/j.gtc.2020.01.006] [Reference Citation Analysis]
30 Nasr JJ, Shalan S. Validated 1H and 19F nuclear magnetic resonance for the quantitative determination of the hepatitis C antiviral drugs sofosbuvir, ledipasvir, and daclatasvir in tablet dosage forms. Microchemical Journal 2020;152:104437. [DOI: 10.1016/j.microc.2019.104437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World J Gastroenterol 2019; 25(29): 3897-3919 [PMID: 31413526 DOI: 10.3748/wjg.v25.i29.3897] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
32 Farid AA, Afify NA, Alsharnoby AA, Abdelsameea E, Bedair HM. Predictive Role of AURKA rs 1047972 Gene Polymorphism and the Risk of Development of Hepatocellular Carcinoma. Immunol Invest 2021;:1-11. [PMID: 34018460 DOI: 10.1080/08820139.2021.1920609] [Reference Citation Analysis]
33 Abdelaty LN, Elnaggar AA, Said AA, Hussein RRS. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. Curr Drug Saf 2020;15:53-60. [PMID: 31573893 DOI: 10.2174/1574886314666191001151314] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Naguib GG, Farid A, Hassan M, Elshafie A, Shazly YE, Shaker MK, Ezzat H, Safwat E, Ahmed OA, Dabbous H, Sherief AF, Hassany M, Elserafy M, Elsayed MH. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience. Arab J Gastroenterol 2021:S1687-1979(21)00043-5. [PMID: 34531135 DOI: 10.1016/j.ajg.2021.06.001] [Reference Citation Analysis]
35 Elabd NS, Tayel SI, Elhamouly MS, Hassanein SA, Kamaleldeen SM, Ahmed FE, Rizk M, Gadallah AA, Ajlan SE, Sief AS. Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals. Hepat Med 2021;13:9-23. [PMID: 33758557 DOI: 10.2147/HMER.S292251] [Reference Citation Analysis]
36 Dzingirai B, Katsidzira L, Matyanga CMJ, Postma MJ, van Hulst M, Mafirakureva N. Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges. J Viral Hepat 2021;28:994-1002. [PMID: 33797190 DOI: 10.1111/jvh.13510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]